Close
Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 2

Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme. To give you a teaser of what is to come, we are taking a closer look at the plenary speakers in the ALS-FTD sessions at the Symposium. In this blog, we explore the topics they will be presenting and find out a little more about the speakers.

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1

Symposium Preview: Meet the ALS/FTD Plenary Speakers…Part 1

Reading Time: 5 minutes Every year, the team works hard to build on the previous year’s success. This year we are excited to include a series of three ALS-FTD joint sessions, in collaboration with the International Society for Frontotemporal Dementias, in the programme.

Some people with ALS, the most common form of MND, also develop a form of dementia known as frontotemporal dementia (FTD). FTD is a group of disorders where the nerve cells in two sets of lobes (frontal and temporal) in the brain are damaged. In a similar way to how motor neurones break down in MND and cause loss of function in muscles, the damage to the nerve cells in FTD causes the connections between parts of the brain to break down. As more cells become damaged and die this can lead to symptoms such as problems with memory, thinking or language, changes in mood, emotions and behaviour.

Behind the headlines: could a potential treatment for MND be developed into a nasal spray?

Behind the headlines: could a potential treatment for MND be developed into a nasal spray?

Reading Time: 6 minutes Recent research, led by Professor Guillaume Hautbergue at the University of Sheffield, has found a potential new method of preventing nerve cell death in the most common genetic form of MND. This new method could, with further studies, lead to the development of a potential therapy for C9orf72 MND, and a type of dementia called…

Cognition and FTD: Highlights from Glasgow

Reading Time: 3 minutes Written by Rachel Boothman and Kaye Stevens This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. Exploration into cognition and frontotemporal dementia with MND/ALS continues to attract attention. At the…